Digital Storytelling in Pediatric Safe Drug

Sponsor

Ege University (Other)

Overall Status

Completed

CT.gov ID

NCT05845957

Collaborator

Izmir Bakircay University (Other)

Enrollment

Location

Arms

15.9

Actual Duration (Months)

5.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Summary Aim: This research was conducted to determine the effectiveness of education given to students using digital storytelling in safe pediatric intravenous drug administration.

Method: It is a randomized controlled experimental study. The sample of the study consisted of 84 nursing students. The students included in the study were divided into two equal groups: the experimental and control groups. Digital education material of the experimental group and theoretical education was applied to the control group. Before and after the training, a post-knowledge test was made and evaluated.

Condition or Disease	Intervention/Treatment	Phase
Education Nursing Innovativeness	Other: Digital Education Group	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

84 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

The research was a randomized controlled, experimental study.The research was a randomized controlled, experimental study.

Masking:

Single (Investigator)

Primary Purpose:

Prevention

Official Title:

The Efficiency of Education Given to Students With Digital Storytelling in Safe Pediatric Intravenous Drug Administration

Actual Study Start Date :

Dec 8, 2021

Actual Primary Completion Date :

Apr 30, 2022

Actual Study Completion Date :

Apr 6, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Digital Education Group All participants in this group were given the "Safe pediatric intravenous drug administration knowledge test" prepared by the researchers as a pre-test. The participants of this group, who were determined by randomization, were given training prepared using the digital storytelling method. The training took 25 minutes. After the training, the "Safe intravenous drug administration knowledge test" was applied as a post-test.	Other: Digital Education Group Providing training on safe pediatric intravenous drug administration with digital storytelling method
No Intervention: Control Group No intervention was made. All participants in this group were given the "Safe pediatric intravenous drug administration knowledge test" prepared by the researchers as a pre-test. Afterward, theoretical information on the subject was given. After theoretical information, the "Safe intravenous drug administration knowledge test" was applied as a post-test.

Arm

Intervention/Treatment

Experimental: Digital Education Group

All participants in this group were given the "Safe pediatric intravenous drug administration knowledge test" prepared by the researchers as a pre-test. The participants of this group, who were determined by randomization, were given training prepared using the digital storytelling method. The training took 25 minutes. After the training, the "Safe intravenous drug administration knowledge test" was applied as a post-test.

Other: Digital Education Group

Providing training on safe pediatric intravenous drug administration with digital storytelling method

No Intervention: Control Group

No intervention was made. All participants in this group were given the "Safe pediatric intravenous drug administration knowledge test" prepared by the researchers as a pre-test. Afterward, theoretical information on the subject was given. After theoretical information, the "Safe intravenous drug administration knowledge test" was applied as a post-test.

Outcome Measures

Primary Outcome Measures

Statistical difference between groups about knowledge test scores [During the education, approximately 25 minutes]
Safe pediatric drug practices knowledge test is applied twice as pre-test and post-test in experimental and control groups. Safe pediatric drug practices knowledge test: It is a 17-question form prepared by researchers. Content validity has been made for the form. Each correct answer is calculated as 1 point and each wrong answer is calculated as 0 points. The higher the score obtained from the questionnaire, the higher the level of knowledge.

Eligibility Criteria

Criteria

Ages Eligible for Study:

19 Years to 23 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Being a student of the Department of Nursing
Taking the child health and diseases nursing course and being successful
Volunteering to participate in the research

Exclusion Criteria:

Participate and quit the study
Being a 1st and 2nd year nursing student
Failure of the child health and diseases nursing course

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Semih	İzmir		Turkey	35665

Sponsors and Collaborators

Ege University
Izmir Bakircay University

Investigators

Principal Investigator: Semih Akkoyun, Izmir Bakircay University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Şeyda BİNAY YAZ, Assistant professor, Ege University

ClinicalTrials.gov Identifier:

NCT05845957

Other Study ID Numbers:

Bakircay

First Posted:

May 6, 2023

Last Update Posted:

May 6, 2023

Last Verified:

May 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Şeyda BİNAY YAZ, Assistant professor, Ege University

safe drug application

Study Results

No Results Posted as of May 6, 2023